Pnc Financial Services Group, Inc. Eagle Pharmaceuticals, Inc. Transaction History

Pnc Financial Services Group, Inc.

$156 Billion
Q3 2024

A detailed history of Pnc Financial Services Group, Inc. transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 28 shares of EGRX stock, worth $15. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 28 -0.0%

Holding current value

$15

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$3.34 - $5.6 $93 - $156	28 New	28 $0
Q3 2023 Nov 13, 2023	SELL	$15.21 - $22.88 $1,551 - $2,333	-102 Reduced 87.18%	15 $0
Q2 2023 Aug 11, 2023	SELL	$17.74 - $31.87 $4,293 - $7,712	-242 Reduced 67.41%	117 $2,000
Q1 2023 May 15, 2023	SELL	$25.06 - $34.09 $6,691 - $9,102	-267 Reduced 42.65%	359 $10,000
Q4 2022 Feb 10, 2023	BUY	$24.98 - $39.77 $5,245 - $8,351	210 Added 50.48%	626 $18,000
Q3 2022 Nov 10, 2022	SELL	$26.42 - $47.12 $10,039 - $17,905	-380 Reduced 47.74%	416 $10,000
Q2 2022 Aug 12, 2022	SELL	$41.26 - $51.35 $3,342 - $4,159	-81 Reduced 9.24%	796 $35,000
Q1 2022 May 12, 2022	SELL	$44.58 - $52.6 $11,679 - $13,781	-262 Reduced 23.0%	877 $43,000
Q4 2021 Feb 11, 2022	SELL	$45.82 - $56.9 $229 - $284	-5 Reduced 0.44%	1,139 $57,000
Q3 2021 Nov 05, 2021	BUY	$43.79 - $55.78 $13,312 - $16,957	304 Added 36.19%	1,144 $63,000
Q2 2021 Aug 06, 2021	BUY	$36.86 - $44.5 $1,990 - $2,403	54 Added 6.87%	840 $35,000
Q1 2021 May 07, 2021	SELL	$40.32 - $50.97 $5,120 - $6,473	-127 Reduced 13.91%	786 $32,000
Q4 2020 Feb 12, 2021	BUY	$41.72 - $51.34 $7,926 - $9,754	190 Added 26.28%	913 $42,000
Q3 2020 Nov 06, 2020	BUY	$37.02 - $51.28 $7,589 - $10,512	205 Added 39.58%	723 $30,000
Q2 2020 Aug 07, 2020	SELL	$43.24 - $55.02 $2,983 - $3,796	-69 Reduced 11.75%	518 $24,000
Q1 2020 May 08, 2020	SELL	$34.37 - $60.07 $9,108 - $15,918	-265 Reduced 31.1%	587 $27,000
Q4 2019 Feb 07, 2020	SELL	$54.32 - $64.31 $1.12 Million - $1.33 Million	-20,612 Reduced 96.03%	852 $51,000
Q3 2019 Nov 08, 2019	SELL	$53.25 - $59.98 $468,600 - $527,824	-8,800 Reduced 29.08%	21,464 $1.21 Million
Q2 2019 Aug 09, 2019	BUY	$46.61 - $58.45 $1.38 Million - $1.73 Million	29,622 Added 4614.02%	30,264 $0
Q1 2019 May 10, 2019	BUY	$38.66 - $51.82 $15,154 - $20,313	392 Added 156.8%	642 $0
Q4 2018 Feb 08, 2019	SELL	$36.72 - $67.73 $771 - $1,422	-21 Reduced 7.75%	250 $10,000
Q2 2018 Aug 10, 2018	BUY	$51.25 - $76.62 $7,380 - $11,033	144 Added 113.39%	271 $0
Q1 2018 May 11, 2018	SELL	$52.16 - $66.86 $60,192 - $77,156	-1,154 Reduced 90.09%	127 $0
Q4 2017 Feb 09, 2018	BUY	$49.6 - $60.87 $7,489 - $9,191	151 Added 13.36%	1,281 $0
Q3 2017 Nov 13, 2017	BUY	$46.62 - $60.36 $52,680 - $68,206	1,130	1,130 $0

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.6M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.16M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.

Account

Pnc Financial Services Group, Inc. Eagle Pharmaceuticals, Inc. Transaction History